Dr Mathew Wilson
@mathewgwilson.bsky.social
Clinical Research Fellow at The Royal Marsden Hospital, London. Medical Oncology. Work focus on #Melanoma and Lung Cancer. Native Scotsman 🏴, adopted New Zealander 🇳🇿. #medsky #oncsky #oncology #lcsm
#OptiTROP-Lung04
🫁Sac-TMT (Trop2 ADC) vs Pt doublet in EGFR mutant #NSCLC 2nd line after targeted therapy
mPFS 8.3 vs 4.3months
mOS Not Reached vs 17.4months
No ILD/pneumonitis. G3 Tox similar in both arms
Exciting option, in a challenging setting
#ESMO25 @oncoalert.bsky.social #LCSM
🫁Sac-TMT (Trop2 ADC) vs Pt doublet in EGFR mutant #NSCLC 2nd line after targeted therapy
mPFS 8.3 vs 4.3months
mOS Not Reached vs 17.4months
No ILD/pneumonitis. G3 Tox similar in both arms
Exciting option, in a challenging setting
#ESMO25 @oncoalert.bsky.social #LCSM
October 19, 2025 at 3:05 PM
#OptiTROP-Lung04
🫁Sac-TMT (Trop2 ADC) vs Pt doublet in EGFR mutant #NSCLC 2nd line after targeted therapy
mPFS 8.3 vs 4.3months
mOS Not Reached vs 17.4months
No ILD/pneumonitis. G3 Tox similar in both arms
Exciting option, in a challenging setting
#ESMO25 @oncoalert.bsky.social #LCSM
🫁Sac-TMT (Trop2 ADC) vs Pt doublet in EGFR mutant #NSCLC 2nd line after targeted therapy
mPFS 8.3 vs 4.3months
mOS Not Reached vs 17.4months
No ILD/pneumonitis. G3 Tox similar in both arms
Exciting option, in a challenging setting
#ESMO25 @oncoalert.bsky.social #LCSM
#HARMOMi-6
🫁Compared Ivonescimab (PD-1 + VEGF bispecific) vs Tizlelizumab (PD1) in combo ŵ Chemo in 1st line setting for squamous #NSCLC
mPFS = 11.1 vs 6.9 months
Benefit preserved across subgroups including PD-L1<1%
OSdata awaited…
No increase in tox
This data is exciting #ESMO25 @OncoAlert
🫁Compared Ivonescimab (PD-1 + VEGF bispecific) vs Tizlelizumab (PD1) in combo ŵ Chemo in 1st line setting for squamous #NSCLC
mPFS = 11.1 vs 6.9 months
Benefit preserved across subgroups including PD-L1<1%
OSdata awaited…
No increase in tox
This data is exciting #ESMO25 @OncoAlert
October 19, 2025 at 2:43 PM
#HARMOMi-6
🫁Compared Ivonescimab (PD-1 + VEGF bispecific) vs Tizlelizumab (PD1) in combo ŵ Chemo in 1st line setting for squamous #NSCLC
mPFS = 11.1 vs 6.9 months
Benefit preserved across subgroups including PD-L1<1%
OSdata awaited…
No increase in tox
This data is exciting #ESMO25 @OncoAlert
🫁Compared Ivonescimab (PD-1 + VEGF bispecific) vs Tizlelizumab (PD1) in combo ŵ Chemo in 1st line setting for squamous #NSCLC
mPFS = 11.1 vs 6.9 months
Benefit preserved across subgroups including PD-L1<1%
OSdata awaited…
No increase in tox
This data is exciting #ESMO25 @OncoAlert
#ESMO25
Adam Gripping of @mdanderson.bsky.social discusses association of improved OS in #NSCLC and #Melanoma with administration of a mRNA COVID vaccine
Translational work showing mechanism of increased INF-alpha leading to immune priming
Phase III in development… @oncoalert.bsky.social
Adam Gripping of @mdanderson.bsky.social discusses association of improved OS in #NSCLC and #Melanoma with administration of a mRNA COVID vaccine
Translational work showing mechanism of increased INF-alpha leading to immune priming
Phase III in development… @oncoalert.bsky.social
October 19, 2025 at 1:22 PM
#ESMO25
Adam Gripping of @mdanderson.bsky.social discusses association of improved OS in #NSCLC and #Melanoma with administration of a mRNA COVID vaccine
Translational work showing mechanism of increased INF-alpha leading to immune priming
Phase III in development… @oncoalert.bsky.social
Adam Gripping of @mdanderson.bsky.social discusses association of improved OS in #NSCLC and #Melanoma with administration of a mRNA COVID vaccine
Translational work showing mechanism of increased INF-alpha leading to immune priming
Phase III in development… @oncoalert.bsky.social
#RAMPART demonstrated improved disease free suvivival at three years in resectable Renal Cell Carcinoma with addition of adjuvant #Durvalumab and #Tremelimumab
3year DFS 81% vs 73% for surveillance
Nb increased tox, including myocarditis
#ESMO25 @oncoalert.bsky.social
3year DFS 81% vs 73% for surveillance
Nb increased tox, including myocarditis
#ESMO25 @oncoalert.bsky.social
October 18, 2025 at 7:31 AM
#RAMPART demonstrated improved disease free suvivival at three years in resectable Renal Cell Carcinoma with addition of adjuvant #Durvalumab and #Tremelimumab
3year DFS 81% vs 73% for surveillance
Nb increased tox, including myocarditis
#ESMO25 @oncoalert.bsky.social
3year DFS 81% vs 73% for surveillance
Nb increased tox, including myocarditis
#ESMO25 @oncoalert.bsky.social
#ALEX study shows 81.1 month median OS in final report of study from Tong Mok
Amongst the longest overall survivals reported in lung cancer. Further trials of 3rd and 4th gen TKI ongoing. Much work to do, but valuable to reflect on how far things have com
#ESMO25 #LCSM #Alk #NSCLC
Amongst the longest overall survivals reported in lung cancer. Further trials of 3rd and 4th gen TKI ongoing. Much work to do, but valuable to reflect on how far things have com
#ESMO25 #LCSM #Alk #NSCLC
October 17, 2025 at 3:29 PM
Phase 2 #NORTHSTAR presented by @YYElamin: improved PFS ŵ addition of local consolidative therapy (Sx or RT) after initiation of Osimertinib for #NSCLC. Acceptable safety profile. Benefit in Oligo & poly metastatic disease. Exciting pathway to explore further... #ESMO25 #LCSM #Oncsky #Medsky
October 17, 2025 at 2:24 PM
@ESMO day1 #ESMO25
Today looking forward to:
-Session on optimising peri-operative IO from @MartinReck2
-ReCIPE-M1 study from Jacob Orme
-session on emerging options beyond CPI chsired. Y Ines Pires de Silva
-Final ALEX data from Tony Mok and Beamion data from Sanjay Popat
@myesmo.bsky.social
Today looking forward to:
-Session on optimising peri-operative IO from @MartinReck2
-ReCIPE-M1 study from Jacob Orme
-session on emerging options beyond CPI chsired. Y Ines Pires de Silva
-Final ALEX data from Tony Mok and Beamion data from Sanjay Popat
@myesmo.bsky.social
October 17, 2025 at 11:15 AM
@ESMO day1 #ESMO25
Today looking forward to:
-Session on optimising peri-operative IO from @MartinReck2
-ReCIPE-M1 study from Jacob Orme
-session on emerging options beyond CPI chsired. Y Ines Pires de Silva
-Final ALEX data from Tony Mok and Beamion data from Sanjay Popat
@myesmo.bsky.social
Today looking forward to:
-Session on optimising peri-operative IO from @MartinReck2
-ReCIPE-M1 study from Jacob Orme
-session on emerging options beyond CPI chsired. Y Ines Pires de Silva
-Final ALEX data from Tony Mok and Beamion data from Sanjay Popat
@myesmo.bsky.social
June 16, 2025 at 8:23 AM
Why does immunotherapy appear to be more effective early in the day?
More work to be done but many aspects of immune system follow circadian rhythm, including dendritic cell migration and entry of circulating tumour cells to circulation
#ImmuneOnc #Oncsky #IO #medsky
jitc.bmj.com/content/13/3...
More work to be done but many aspects of immune system follow circadian rhythm, including dendritic cell migration and entry of circulating tumour cells to circulation
#ImmuneOnc #Oncsky #IO #medsky
jitc.bmj.com/content/13/3...
June 9, 2025 at 4:35 PM
Why does immunotherapy appear to be more effective early in the day?
More work to be done but many aspects of immune system follow circadian rhythm, including dendritic cell migration and entry of circulating tumour cells to circulation
#ImmuneOnc #Oncsky #IO #medsky
jitc.bmj.com/content/13/3...
More work to be done but many aspects of immune system follow circadian rhythm, including dendritic cell migration and entry of circulating tumour cells to circulation
#ImmuneOnc #Oncsky #IO #medsky
jitc.bmj.com/content/13/3...
🌟🌟CHALLENGE trial:
3year structured exercise program after adjuvant chemo improved DFS (ie. Alive & cancer free) in stage II/III colon cancer
5year DFS 80.3 vs 73.9%, HR 0.72
Amazing work, needs to be repeated in other tumour streams and paradigms
#Oncsky #Cansky #Medsky #exercise #survivorship
3year structured exercise program after adjuvant chemo improved DFS (ie. Alive & cancer free) in stage II/III colon cancer
5year DFS 80.3 vs 73.9%, HR 0.72
Amazing work, needs to be repeated in other tumour streams and paradigms
#Oncsky #Cansky #Medsky #exercise #survivorship
June 5, 2025 at 8:16 PM
🌟🌟CHALLENGE trial:
3year structured exercise program after adjuvant chemo improved DFS (ie. Alive & cancer free) in stage II/III colon cancer
5year DFS 80.3 vs 73.9%, HR 0.72
Amazing work, needs to be repeated in other tumour streams and paradigms
#Oncsky #Cansky #Medsky #exercise #survivorship
3year structured exercise program after adjuvant chemo improved DFS (ie. Alive & cancer free) in stage II/III colon cancer
5year DFS 80.3 vs 73.9%, HR 0.72
Amazing work, needs to be repeated in other tumour streams and paradigms
#Oncsky #Cansky #Medsky #exercise #survivorship
Arrived home to find a copy of #ADifferentKindOfPower by truly great New Zealander @jacindaardern.bsky.social on my doorstep. Excited to give it a read - update will follow
#NewZealand #NZ #booksky #Power #kindness #aotearoa
#NewZealand #NZ #booksky #Power #kindness #aotearoa
June 5, 2025 at 5:38 PM
Arrived home to find a copy of #ADifferentKindOfPower by truly great New Zealander @jacindaardern.bsky.social on my doorstep. Excited to give it a read - update will follow
#NewZealand #NZ #booksky #Power #kindness #aotearoa
#NewZealand #NZ #booksky #Power #kindness #aotearoa
Multiple oral abstracts & posters @ascocancer.bsky.social present evidence that Time of Day impacts on effectiveness of immunotherapy. With morning administration improving outcomes
Easy to implement 👍
No additional $$ cost 👍
Tolerable for most patients 👍
#Oncsky #Medsky #Cansky #LCSM #IO
Easy to implement 👍
No additional $$ cost 👍
Tolerable for most patients 👍
#Oncsky #Medsky #Cansky #LCSM #IO
June 4, 2025 at 3:37 PM
Everything is Tuberculosis by @johngreensbluesky.bsky.social Thoughtful writing on how society engages with disease, and how illness effects society
Short enough to read on a flight. Concise arguaments & keeps swift pace. Would be accessible for a young person with a curious mind
#TB #VirtousCycle
Short enough to read on a flight. Concise arguaments & keeps swift pace. Would be accessible for a young person with a curious mind
#TB #VirtousCycle
April 19, 2025 at 12:46 AM
Everything is Tuberculosis by @johngreensbluesky.bsky.social Thoughtful writing on how society engages with disease, and how illness effects society
Short enough to read on a flight. Concise arguaments & keeps swift pace. Would be accessible for a young person with a curious mind
#TB #VirtousCycle
Short enough to read on a flight. Concise arguaments & keeps swift pace. Would be accessible for a young person with a curious mind
#TB #VirtousCycle
Goodbye for now New Zealand. You’ve been excellent. And so have I.
Onwards
#Aotearoa #NewZealand #NZ #ThankYou #onwards
Onwards
#Aotearoa #NewZealand #NZ #ThankYou #onwards
April 18, 2025 at 2:37 AM
Goodbye for now New Zealand. You’ve been excellent. And so have I.
Onwards
#Aotearoa #NewZealand #NZ #ThankYou #onwards
Onwards
#Aotearoa #NewZealand #NZ #ThankYou #onwards
April 5, 2025 at 1:54 AM
West Island has it’s moments, but you can’t beat New Zealand on a good day 🥝🐏🇳🇿
March 30, 2025 at 3:40 AM
West Island has it’s moments, but you can’t beat New Zealand on a good day 🥝🐏🇳🇿
Try New Zealand. Sure we have regular earthquakes, a species of three eyed lizard, no land based predators and an official wizard, but in 2025 you’re the weirdo.
February 15, 2025 at 11:20 AM
Try New Zealand. Sure we have regular earthquakes, a species of three eyed lizard, no land based predators and an official wizard, but in 2025 you’re the weirdo.
Phase I/II of Nivo vs Ipi+Nivo in advanced Merkel Cell Carcinoma
Similar efficacy in both groups, ORR 60 vs 58%. ++toxicity with Ipi
No benefit to adding Ipi in this study, but important to ask the question in a rare cancer
#Oncsky #MedSky #Immuneoncology #RareCancers
doi.org/10.1200/JCO-...
Similar efficacy in both groups, ORR 60 vs 58%. ++toxicity with Ipi
No benefit to adding Ipi in this study, but important to ask the question in a rare cancer
#Oncsky #MedSky #Immuneoncology #RareCancers
doi.org/10.1200/JCO-...
February 5, 2025 at 10:03 AM
Phase I/II of Nivo vs Ipi+Nivo in advanced Merkel Cell Carcinoma
Similar efficacy in both groups, ORR 60 vs 58%. ++toxicity with Ipi
No benefit to adding Ipi in this study, but important to ask the question in a rare cancer
#Oncsky #MedSky #Immuneoncology #RareCancers
doi.org/10.1200/JCO-...
Similar efficacy in both groups, ORR 60 vs 58%. ++toxicity with Ipi
No benefit to adding Ipi in this study, but important to ask the question in a rare cancer
#Oncsky #MedSky #Immuneoncology #RareCancers
doi.org/10.1200/JCO-...
31/365
1 month into exercising every day of 2025
I still have the body shape of a potato, but you gotta start somewhere. So far: energy up, sleep improved and enjoying the change in routine
#fitness #gym #health #weightloss #newyearsresolution #fitnesssky #gymsky
1 month into exercising every day of 2025
I still have the body shape of a potato, but you gotta start somewhere. So far: energy up, sleep improved and enjoying the change in routine
#fitness #gym #health #weightloss #newyearsresolution #fitnesssky #gymsky
February 1, 2025 at 8:11 AM
31/365
1 month into exercising every day of 2025
I still have the body shape of a potato, but you gotta start somewhere. So far: energy up, sleep improved and enjoying the change in routine
#fitness #gym #health #weightloss #newyearsresolution #fitnesssky #gymsky
1 month into exercising every day of 2025
I still have the body shape of a potato, but you gotta start somewhere. So far: energy up, sleep improved and enjoying the change in routine
#fitness #gym #health #weightloss #newyearsresolution #fitnesssky #gymsky
CheckMate-067 10year final analysis:
Ipi/Nivo:
📍median Melanoma Specific Survival=NOT REACHED at 120months
📍mOS=71.9months
📍For those alive @ 3years, melanoma specific survival at 10years=96%
📍No new safety signal >5years
Cure for some
#Oncsky #Cansky #Melanoma #IO
www.nejm.org/doi/full/10....
Ipi/Nivo:
📍median Melanoma Specific Survival=NOT REACHED at 120months
📍mOS=71.9months
📍For those alive @ 3years, melanoma specific survival at 10years=96%
📍No new safety signal >5years
Cure for some
#Oncsky #Cansky #Melanoma #IO
www.nejm.org/doi/full/10....
January 7, 2025 at 8:49 AM
CheckMate-067 10year final analysis:
Ipi/Nivo:
📍median Melanoma Specific Survival=NOT REACHED at 120months
📍mOS=71.9months
📍For those alive @ 3years, melanoma specific survival at 10years=96%
📍No new safety signal >5years
Cure for some
#Oncsky #Cansky #Melanoma #IO
www.nejm.org/doi/full/10....
Ipi/Nivo:
📍median Melanoma Specific Survival=NOT REACHED at 120months
📍mOS=71.9months
📍For those alive @ 3years, melanoma specific survival at 10years=96%
📍No new safety signal >5years
Cure for some
#Oncsky #Cansky #Melanoma #IO
www.nejm.org/doi/full/10....